Founded in 2016 by Michael J. Cerminaro, Thrombolex develops and distributes endovascular catheters used in interventional procedures, specifically in catheter-directed thrombolysis. The company offers seven FDA-cleared devices based on the BASHIR™ Endovascular Catheter platform technology, which enables hospitals to improve treatment outcomes for patients with arterial and venous thromboembolic conditions. Thrombolex is focused on creating catheters that enhance the flow of thrombolytics into thrombus, reducing treatment time and the need for higher doses of drugs.